Impact of immunotherapy in overall survival improvement in patients with metastatic urothelial bladder cancer

Postgraduate Thesis uoadl:2937429 96 Read counter

Unit:
Κατεύθυνση Κλινικές Μελέτες: Σχεδιασμός και Εκτέλεση
Library of the School of Health Sciences
Deposit date:
2021-03-19
Year:
2021
Author:
Avlonitou Maria
Supervisors info:
Φλώρα Ζαγουρή, Αναπληρώτρια Καθηγήτρια,Ιατρική Σχολή ΕΚΠΑ
Σεργεντάνης Θεόδωρος, Ακαδημαικός υπότροφος,Ιατρική Σχολή ΕΚΠΑ
Γαβριατοπούλου Μαρία, Επίκουρη καθηγήτρια,Ιατρική Σχολή ΕΚΠΑ
Original Title:
Η συμβολή της ανοσοθεραπείας στην βελτίωση της μέσης επιβίωση ασθενών με μεταστατικό ουροθηλιακό καρκίνο της ουροδόχου κύστεως.
Languages:
Greek
English
Translated title:
Impact of immunotherapy in overall survival improvement in patients with metastatic urothelial bladder cancer
Summary:
Urothelial cancer (UC) is the most common histological cancer type arising from the epithelium that covers the urinary tract. Approximately 75% of patients with bladder cancer are diagnosed with non-invasive bladder cancer, which is usually treated with repeated local treatment under close monitoring. However, 25% of patients suffering from urethral cancer will be diagnosed with muscle-invasive cancer, which requires aggressive treatment, such as radical cystectomy and chemotherapy. The prognosis of metastatic urothelial cancer is poor Cisplatin-based chemotherapy is the standard of care for the metastatic urothelial cancer, while the development of new treatment options is slowly evolving. The scope of the present study is to evaluate the impact of immunological therapeutic options on the metastatic bladder cancer. For this purpose, the use of immunotherapy in the treatment of metastatic urinary bladder carcinoma was studied through a bibliographic research of published medical works and clinical studies. The literature review was performed using PRISMA analysis and is based on a search of international literature from 2000 to 2020. The results of the study demonstrated that the administration of immunotherapeutic drug substances such as pembrolizumab, durvalumab, nivolumab, avelumab and atezolizumab improves the mean overall survival of patients, whether some of these medications have been studied with respect to their action on the progression free survival with less frequent or severe adverse events. Immunotherapy is recommended as first line treatment in cisplatin ineligible with high PDL-1 expression patients , as first line maintenance therapy after administration of chemotherapy and as second line treatment upon disease progression on platinum based regiment . The current study demonstrated the value of immunotherapy against the metastatic urothelial bladder cancer by conducting a bibliographic research and an overall summary of the most recent clinical studies on this specific clinical field.
Main subject category:
Health Sciences
Keywords:
Urothelial ,cancer, Cancer, Bladder, Immunotherapy
Index:
No
Number of index pages:
0
Contains images:
Yes
Number of references:
50
Number of pages:
64
File:
File access is restricted only to the intranet of UoA.

Avlonitou Maria.pdf
1 MB
File access is restricted only to the intranet of UoA.